MYLK3

Across TCGA pan-cancer cohorts, MYLK3 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated MYLK3 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MYLK3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYLK3 expression acts as an unfavorable survival marker.

ESCA, COAD, and LIHC are the cancer types where MYLK3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.105	0.539	<.001	24	view →
COAD	OS	Median	II,III,IV	0.188	0.605	.004	23	view →
LIHC	OS	Median	All	0.098	0.774	.001	18	view →
OV	OS	Median	IV	0.022	0.760	<.001	12	view →
BLCA	OS	Median	III,IV	0.130	0.684	<.001	12	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SCLC	DFS	Median	II,III,IV	0.164	0.602	.021	6	view →
LUAD	DFS	Median	II,III,IV	0.178	0.721	.008	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
KIRP	OS	Median	II,III,IV	0.199	0.771	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MYLK3–ESCA (DFS)

Open the ESCA breakdown →